Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mannan-conjugated grass pollen allergoid vaccine
- Development stage
- Unknown
- Lead developer
- Inmunotek
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
A subcutaneous allergen immunotherapy (AIT) vaccine developed by Inmunotek S.L. for the treatment of grass pollen-induced allergic rhinitis and rhinoconjunctivitis. The vaccine consists of polymerized allergoids from *Dactylis glomerata* (orchard grass) and *Phleum pratense* (timothy grass) pollen, which are chemically conjugated to mannan (a carbohydrate from *Saccharomyces cerevisiae*). This conjugation targets C-type lectin receptors, specifically the mannose receptor (CD206), on dendritic cells. This targeting enhances allergen uptake and processing, promoting the induction of regulatory T cells (Tregs) and the production of anti-inflammatory cytokines like IL-10, thereby shifting the immune response from a Th2-allergic profile toward long-term immune tolerance.
- Other names
- mannan-conjugated grass pollen allergoidpolymerised mannan-conjugated Dactylis glomerata/Phleum pratense allergoid vaccine
02
Targets
CD209 (Dendritic cell-specific intercellular adhesion Molecule-3-Grabbing non-integrin)
Beyond the preview
Go deeper on mannan-conjugated grass pollen allergoid vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mannan-conjugated grass pollen allergoid vaccine.